UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 9, 2018
GT Biopharma, Inc.
(Exact
name of Registrant as specified in its charter)
|
Delaware
|
000-08092
|
94-1620407
|
|
(State
or other Jurisdiction of Incorporation or
organization)
|
(Commission
File Number)
|
(IRS
Employer I.D. No.)
|
1825 K Street
Suite 510
Washington, D.C. 20006
Phone: (800) 304-9888
(Address,
including zip code, and telephone number, including area code,
of
registrant’s
principal executive offices)
N/A
(Former
name, former address and former fiscal year, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l
4a- l 2)
☐
Pre-commencement
communications pursuant to Rule l 4d-2(b) under the Exchange Act
(17 CFR 240. l 4d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240. l 3e-4(c))
ITEM 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On May 9, 2018, Dr. Raymond Urbanski was appointed to be the
President of GT Biopharma, Inc. (hereinafter the
“Company”) by the Board of Directors. Dr.
Urbanski will also remain as the Chief Medical Officer of the
Company. Also, Dr. Urbanski’s compensation will remain
unchanged. Dr. Urbanski’s contract was for three years. Under
the terms of his contract, he received a restricted stock award
of 1,528,898 common shares that
vests over two years and is paid an annual salary of
$400,000.
Dr. Urbanski has been our Chief
Medical Officer since September 2017. Before joining us, he was the
Chief Medical Officer for MannKind Corporation (NASDAQ:MNKD) from
August 2015 to September 2017. He was the Chief Medical Officer for
Mylan Inc. (NASDAQ:MYL) from August 2012 to September 2014. Dr.
Urbanski spent eight years with Pfizer Inc. (NYSE:PFE), or Pfizer,
and held several positions with Pfizer, including Vice President
and Chief Medical Officer of the Established Products Business
Unit, Senior Medical Director of Oncology Clinical R&D, Senior
Medical Director of Breast Cancer Products and Medical Director of
Diversified Products. He brings extensive experience in developing
and overseeing clinical studies, including Phase 3b and Phase 4
studies (including line extensions) for sunitinib (Sutent),
exemestane (Aromasin), irinotecan (Camptosar), epirubicin
(Ellence), axitinib, IGF1R inhibitor, and tremilimumab. In addition
to his role with Pfizer, Dr. Urbanski has also served as chief
medical officer of Metabolex Inc. from October 2011 to June 2012,
and senior director of U.S. Medical Affairs for Aventis
(NYSE:SNY).
Dr. Ubanski received his Ph.D, and M.D. from the University of
Medicine and Dentistry of New Jersey – New Jersey Medical
School.
A copy of the press release announcing the appointment of Dr.
Urbanski is attached as Exhibits 99.1 of this Current Report
on Form 8-K.
ITEM 9.01 Exhibits.
Press Release, dated May 14, 2018
SIGNATURE PAGE
Pursuant
to the requirement of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GT Biopharma, Inc.
|
|
|
|
|
|
|
|
|
Dated:
May 14, 2018
|
|
By:
|
/s/
Steven Weldon
|
|
|
|
|
|
Steven
Weldon
|
|
|
|
|
|
Chief
Financial Officer
|
|